AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17008336 — intervention group
Group type: COMPARATOR
Intervention: Relaxation group (n=86)
Number of subjects: 183
Study 15249451 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐radiation‐dose spiral CT (LDCT) scan
Number of subjects: 3318
Study 15249451 — intervention group
Group type: COMPARATOR
Intervention: Chest radiograph (CXR)
Number of subjects: 3318
Study 12034159 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels measured in patients with heart failure
Number of subjects: 76
Study 12034159 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA functional class on discharge
Number of subjects: 76
Study 12034159 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels >0.9 mg/dl
Number of subjects: 76
Study 12034159 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels, NYHA class, plasmatic K on discharge, left ventricle ejection fraction
Number of subjects: 76
Study 12034159 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for 18 months
Number of subjects: 76
Study 9807674 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-thalassaemia trait screening
Number of subjects: 1650
Study 9807674 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcytic subjects screening
Number of subjects: 1650
Study 9807674 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrimination functions for beta-thalassaemia trait
Number of subjects: 1650
Study 7652502 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem monotherapy
Number of subjects: 0
Study 7652502 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime-based regimens
Number of subjects: 0
Study 2524166 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ng.kg‐1.min‐1 ANF infusion
Number of subjects: 22
Study 2524166 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 ng.kg‐1.min‐1 ANF infusion
Number of subjects: 22
Study 2524166 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 22
Study 1119691 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate bilateral oophoroadrenalectomy
Number of subjects: 122
Study 1119691 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy without endocrine ablation
Number of subjects: 122
Study 31629404 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate NMB with sugammadex reversal
Number of subjects: 55
Study 31629404 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate NMB with neostigmine reversal
Number of subjects: 55
Study 31629404 — intervention group
Group type: COMPARATOR
Intervention: Shallow NMB with sugammadex reversal
Number of subjects: 55
Study 31629404 — intervention group
Group type: COMPARATOR
Intervention: Shallow NMB with no reversal
Number of subjects: 55
Study 28750942 — intervention group
Group type: EXPERIMENTAL
Intervention: Hovenia dulcis Thunb. fruit extract (HDE) 2460mg
Number of subjects: 26
Study 28750942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 28750942 — intervention group
Group type: EXPERIMENTAL
Intervention: Hovenia dulcis Thunb. fruit extract (HDE)
Number of subjects: 26
Study 26454835 — intervention group
Group type: EXPERIMENTAL
Intervention: memantine 30mg
Number of subjects: 80
Study 26454835 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 24097301 — intervention group
Group type: EXPERIMENTAL
Intervention: CPV (AES Ultra CPV™)
Number of subjects: 170
Study 24097301 — intervention group
Group type: COMPARATOR
Intervention: LMA (LMA Classic™)
Number of subjects: 170
Study 21751854 — intervention group
Group type: EXPERIMENTAL
Intervention: Running on grass
Number of subjects: 20
Study 21751854 — intervention group
Group type: COMPARATOR
Intervention: Running on asphalt
Number of subjects: 20
Study 19333080 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified chick embryo cell rabies vaccine administered intramuscularly or intradermally
Number of subjects: 0
Study 19333080 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis vaccine
Number of subjects: 0
Study 16394700 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled thoracic epidural analgesia
Number of subjects: 113
Study 16394700 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia followed by patient-controlled analgesia with intravenous morphine
Number of subjects: 113
Study 15235161 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.1 mg/kg/dose intravenously, 3 doses)
Number of subjects: 115
Study 15235161 — intervention group
Group type: COMPARATOR
Intervention: Control (standard neonatal intensive care)
Number of subjects: 115
Study 11726250 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate loading (20 g per day for 7 days)
Number of subjects: 31
Study 11726250 — intervention group
Group type: COMPARATOR
Intervention: Placebo loading
Number of subjects: 31
Study 9233870 — intervention group
Group type: COMPARATOR
Intervention: Educational program taught by physical therapists, consisting of a two-session back school (three hours of training) followed by three to four reinforcement sessions over several years.
Number of subjects: 4000
Study 7895385 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant haemostasis
Number of subjects: 50
Study 7895385 — intervention group
Group type: COMPARATOR
Intervention: Diathermy haemostasis
Number of subjects: 50
Study 2855221 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol-adrenaline infusion
Number of subjects: 0
Study 2855221 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 2855221 — intervention group
Group type: COMPARATOR
Intervention: Supramaximal dose of GRF 1-44 (200 micrograms, i.v.)
Number of subjects: 0
Study 30860410 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring foam rolling
Number of subjects: 15
Study 30860410 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacrosse ball on the plantar surface of the foot
Number of subjects: 15
Study 30860410 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both interventions
Number of subjects: 15
Study 30860410 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study 29729589 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent visual feedback (VF)
Number of subjects: 24
Study 29729589 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent visual feedback (VF)
Number of subjects: 24
Study 29729589 — intervention group
Group type: COMPARATOR
Intervention: No visual feedback (VF)
Number of subjects: 24
Study 28512069 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES) with ultra-thin struts and biodegradable polymer
Number of subjects: 330
Study 28512069 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES) with thin struts and durable polymer
Number of subjects: 330
Study 26651542 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping above the perineum
Number of subjects: 101
Study 26651542 — intervention group
Group type: COMPARATOR
Intervention: Delayed cord clamping below the perineum
Number of subjects: 101
Study 24177278 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative dental implant design with tapered and cylindrical shape, placed under different protocols.
Number of subjects: 141
Study 21164352 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (16.2 mg for AA, 16.6 mg for CA)
Number of subjects: 231
Study 21164352 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 231
Study 18321302 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri ATCC 55730
Number of subjects: 40
Study 18321302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17361520 — intervention group
Group type: EXPERIMENTAL
Intervention: Shehuang Paste (SHP) navel sticking, applied once a day for one month
Number of subjects: 59
Study 17361520 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic treatment including liver protecting medicines, diuretics, and supportive drugs)
Number of subjects: 59
Study 12968235 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK therapy
Number of subjects: 20
Study 12968235 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 11044775 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day
Number of subjects: 268
Study 11044775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 8811135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS) toothpaste
Number of subjects: 30
Study 8811135 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoamidopropyl betaine (CAPB) toothpaste
Number of subjects: 30
Study 8811135 — intervention group
Group type: COMPARATOR
Intervention: Detergent-free paste
Number of subjects: 30
Study 1418507 — intervention group
Group type: EXPERIMENTAL
Intervention: DuoDERM Burn Pack Hydroactive Dressings (DHD)
Number of subjects: 48
Study 1418507 — intervention group
Group type: COMPARATOR
Intervention: silver sulphadiazine/Bactigras dressings (SSD/Bactigras)
Number of subjects: 48
Study 6702863 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide (thiazide)
Number of subjects: 0
Study 6702863 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (beta-blocker)
Number of subjects: 0
Study 6702863 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide treatment
Number of subjects: 0
Study 30442030 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged slow expiration respiratory physiotherapy treatment
Number of subjects: 80
Study 30442030 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 80
Study 30066937 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe polysaccharide (APS) at doses of 20, 40, and 80 µg/ml
Number of subjects: 0
Study 30066937 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe polysaccharide (APS)
Number of subjects: 0
Study 30066937 — intervention group
Group type: COMPARATOR
Intervention: TNF-a
Number of subjects: 0
Study 27217345 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ASCs (2 × 10(6) cells)
Number of subjects: 18
Study 27217345 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose ASCs (10 × 10(6) cells)
Number of subjects: 18
Study 27217345 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ASCs (50 × 10(6) cells)
Number of subjects: 18
Study 27217345 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of ASCs
Number of subjects: 18
Study 24675507 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib
Number of subjects: 132
Study 24675507 — intervention group
Group type: COMPARATOR
Intervention: best supportive care
Number of subjects: 132
Study 23008325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU), cisplatin, and interferon alfa‐2b (IFN α‐2b) plus radiotherapy
Number of subjects: 132
Study 23008325 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil (FU) monotherapy
Number of subjects: 132
Study 20362850 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fluidic parameters (aspiration flow rate 25 cc/min; bottle height 70 cm and 90 cm; vacuum ≤400 mm Hg)
Number of subjects: 0
Study 20362850 — intervention group
Group type: COMPARATOR
Intervention: High fluidic parameters (aspiration flow rate 40 cc/min; bottle height 90 cm and 110 cm; vacuum ≤650 mm Hg)
Number of subjects: 0
Study 20362850 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fluidic parameters
Number of subjects: 0
Study 20362850 — intervention group
Group type: COMPARATOR
Intervention: High fluidic parameters
Number of subjects: 0
Study 18613861 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 100 mg, 200 mg, and 400 mg single doses (study 1)
Number of subjects: 24
Study 18613861 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 100 mg twice daily for 7 days (study 2)
Number of subjects: 24
Study 15970290 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/day for 6 months)
Number of subjects: 75
Study 15970290 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (3.9 mg/week for 6 months)
Number of subjects: 75
Study 15970290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 11854872 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia combined with general anesthesia during surgery and epidural analgesia for the first 24 postoperative hours
Number of subjects: 60
Study 11854872 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia during surgery and intravenous opiate analgesia after surgery
Number of subjects: 60
Study 11703279 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral liarozole 75 mg twice daily for 12 weeks
Number of subjects: 15
Study 11703279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9413412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 52
Study 9413412 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 52
Study 9413412 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 52
Study 8314680 — intervention group
Group type: EXPERIMENTAL
Intervention: H.E.L.P. application (Group A)
Number of subjects: 42
Study 8314680 — intervention group
Group type: EXPERIMENTAL
Intervention: H.E.L.P. application (Group B)
Number of subjects: 42
Study 8314680 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 42
Study 8314680 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 42
Study 3725001 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (200 mg)
Number of subjects: 272
Study 3725001 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (400 mg)
Number of subjects: 272
Study 3725001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 31996411 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride/hydrochlorothiazide (5 mg/50 mg daily)
Number of subjects: 26
Study 31996411 — intervention group
Group type: COMPARATOR
Intervention: Dietary sodium restriction (60 mmol per day)
Number of subjects: 26
Study 29718920 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental cord drainage
Number of subjects: 226
Study 29718920 — intervention group
Group type: COMPARATOR
Intervention: Control group (not submitted to placental cord drainage)
Number of subjects: 226
Study 27180444 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil/hydrochlorothiazide 20/12.5 mg
Number of subjects: 0
Study 27180444 — intervention group
Group type: COMPARATOR
Intervention: Olmetec Plus 20/12.5 mg
Number of subjects: 0
Study 26214787 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 100
Study 26214787 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 100
Study 26214787 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with BIS monitoring
Number of subjects: 100
Study 26214787 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with BIS monitoring
Number of subjects: 100
Study 23763557 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine applied using the DASD
Number of subjects: 50
Study 23763557 — intervention group
Group type: COMPARATOR
Intervention: Control device
Number of subjects: 50
Study 21148499 — intervention group
Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02 3.7 × 10(5) PFU
Number of subjects: 4
Study 21148499 — intervention group
Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02 3.7 × 10(4) PFU
Number of subjects: 4
Study 21148499 — intervention group
Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02 3.7 × 10(3) PFU
Number of subjects: 4
Study 21148499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 21148499 — intervention group
Group type: EXPERIMENTAL
Intervention: ChimeriVax‐WN02 3.7 × 10(5) PFU (part 2)
Number of subjects: 4
Study 21148499 — intervention group
Group type: COMPARATOR
Intervention: Placebo (part 2)
Number of subjects: 4
Study 18294393 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized NYHA adapted protocol (5 or 10 Watt/min stages)
Number of subjects: 22
Study 18294393 — intervention group
Group type: COMPARATOR
Intervention: Standardized Jones protocol (16 Watt per minute stages)
Number of subjects: 22
Study 18294393 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 22
Study 17163251 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine
Number of subjects: 60
Study 17163251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17163251 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 60
Study 12669745 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual organization processes in visual agnosia
Number of subjects: 2
Study 10880159 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic artery chemotherapeutic embolization combined with perfusing LAK cells/interleukin 2
Number of subjects: 42
Study 10880159 — intervention group
Group type: COMPARATOR
Intervention: Hepatic artery chemotherapeutic embolization
Number of subjects: 42
Study 7503472 — intervention group
Group type: EXPERIMENTAL
Intervention: Event monitors
Number of subjects: 43
Study 7503472 — intervention group
Group type: COMPARATOR
Intervention: 48-hour Holter monitoring
Number of subjects: 43
Study 1564675 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 35
Study 1564675 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol
Number of subjects: 35
Study 28837819 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual exposure to vegetables (place mats with pictures of vegetables for 2 weeks)
Number of subjects: 70
Study 28837819 — intervention group
Group type: EXPERIMENTAL
Intervention: Diverse visual exposure to vegetables (varying in color)
Number of subjects: 70
Study 28837819 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual exposure to vegetables
Number of subjects: 70
Study 27037091 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin (G-GR) 1,800 mg once-daily
Number of subjects: 556
Study 25910081 — intervention group
Group type: EXPERIMENTAL
Intervention: Home food environment characteristics (e.g., healthy shopping, selecting healthy beverages, healthy food preparation, serving behaviors)
Number of subjects: 198
Study 25910081 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating while watching television
Number of subjects: 198
Study 25910081 — intervention group
Group type: EXPERIMENTAL
Intervention: Home food environment factors
Number of subjects: 198
Study 25910081 — intervention group
Group type: COMPARATOR
Intervention: Demographic characteristics
Number of subjects: 198
Study 23497000 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial Falls Prevention Program (12-week duration)
Number of subjects: 612
Study 23497000 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial Falls Prevention Program
Number of subjects: 612
Study 23497000 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 612
Study 19716266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological interventions with placebo or blinded care providers
Number of subjects: 184
Study 19716266 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size greater than 100 patients
Number of subjects: 184
Study 19716266 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial quality measures (blinding, placebo use, allocation procedure, overall quality)
Number of subjects: 184
Study 18794646 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 93
Study 18794646 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 93
Study 16647914 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynecological treatment plus somatocognitive therapy
Number of subjects: 0
Study 16647914 — intervention group
Group type: COMPARATOR
Intervention: Standard gynecological treatment
Number of subjects: 0
Study 14657888 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 7165
Study 14657888 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy
Number of subjects: 7165
Study 11122178 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 44
Study 11122178 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 44
Study 8843262 — intervention group
Group type: EXPERIMENTAL
Intervention: Carter‐Thomason Needle‐Point Suture Passer
Number of subjects: 32
Study 8843262 — intervention group
Group type: COMPARATOR
Intervention: Standard technique of hand‐sutured closure
Number of subjects: 32
Study 1624241 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 50 mg
Number of subjects: 38
Study 1624241 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim 50 mg
Number of subjects: 38
Study 6143965 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-LPS treatment (freeze-dried human plasma rich in anti-LPS immunoglobulin G)
Number of subjects: 33
Study 6143965 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 33
Study 6143965 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-LPS treatment
Number of subjects: 33
Study 30898550 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine mesylate (32 mg/kg per day) for 3 consecutive days
Number of subjects: 294
Study 30898550 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) infusions for 3 consecutive days
Number of subjects: 294
Study 30898550 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine mesylate
Number of subjects: 294
Study 30898550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study 26899537 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term statin treatment
Number of subjects: 7746
Study 26899537 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose statins
Number of subjects: 7746
Study 25412647 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza immunization in healthy children
Number of subjects: 0
Study 25412647 — intervention group
Group type: COMPARATOR
Intervention: No immunization (Control)
Number of subjects: 0
Study 23214255 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine
Number of subjects: 46
Study 23214255 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine + Compound Xuanju Capsule (CXC)
Number of subjects: 46